June 15, 2020 / 11:04 AM / 19 days ago

Eli Lilly starts late-stage study of arthritis drug in COVID-19 patients

June 15 (Reuters) - U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.

The company said it was looking to enroll 400 patients in the trial to be conducted in the United States, Europe and Latin America, with results expected in the next few months. (reut.rs/3fihLWq) (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below